Podcast Episodes
Back to Search
Jun 11, 2026 | Takeda Zasocitinib Beats Sotyktu in Head-to-Head Phase 3; Summit Pulls $500M Offering
Zasocitinib hits 35% complete skin clearance at week 16,topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates …
3 months, 1 week ago
Jun 10, 2026 | Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3
Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for r…
3 months, 1 week ago
ADA 2026 Special: The full recap
The Pharma Closeout's full recap of the American Diabetes Association's 86th Scientific Sessions (New Orleans,June 5-8, 2026) - the meeting that ende…
3 months, 1 week ago
The AI Vendor Draft — How Big Pharma Picked Its AI Partners | The Pharma Closeout Special Report
In about six weeks this spring, four of the biggest names in pharma each picked an AI partner — Bristol Myers Squibb chose Anthropic's Claude for 30,…
3 months, 1 week ago
Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data
Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hit…
3 months, 1 week ago
Jun 04, 2026 | SCOTUS Backs Hikma Skinny-Label Win on Vascepa; ADC Therapeutics Crashes 50% on Death
SCOTUS unanimously backs Hikma's skinny-label Vascepa generic, reshaping patent defense for branded pharma. ADC Therapeutics drops 50%+ on LOTIS-5 de…
3 months, 2 weeks ago
ASCO 2026 Special, Part 2 — ThClosing Days: Iza-bren Doubles Down in TNBC & Esophageal
Part 2 of The Pharma Closeout's ASCO 2026 special covers the closing days, Monday
June 1 and Tuesday June 2 — net-new readouts plus resolution of Part…
3 months, 2 weeks ago
ASCO 2026 Special — Comprehensive Opening Weekend: Daraxonrasib Doubles Pancreatic OS
ASCO 2026 comprehensive opening-weekend recap (28 readouts through Sunday, May 31). Headline: Revolution Medicines' RASolute 302 doubles overall surv…
3 months, 2 weeks ago
May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS
RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Pl…
3 months, 2 weeks ago
May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3
Pfizer and Innovent strike a deal worth up to $10.5B for 12 cancer programs — the sixth mega-licensing deal out of China since last July. BMS wins Ph…
3 months, 3 weeks ago